American Association for Cancer Research
10780432ccr162943-sup-174999_4_supp_4098927_8rhw9n.png (3.88 MB)

Figure S1 from Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models

Download (3.88 MB)
posted on 2023-03-31, 20:12 authored by Michelle L. Cook Sangar, Laura A. Genovesi, Madison W. Nakamoto, Melissa J. Davis, Sue E. Knobluagh, Pengxiang Ji, Amanda Millar, Brandon J. Wainwright, James M. Olson

Figure S1 shows the delineation of the tumor in MRI images.




Seattle Children's Brain Tumor Endowment

Kids Cancer Project

Cure Brain Cancer Foundation

Brainchild Foundation



Purpose: Bioinformatics analysis followed by in vivo studies in patient-derived xenograft (PDX) models were used to identify and validate CDK 4/6 inhibition as an effective therapeutic strategy for medulloblastoma, particularly group 3 MYC-amplified tumors that have the worst clinical prognosis.Experimental Design: A protein interaction network derived from a Sleeping Beauty mutagenesis model of medulloblastoma was used to identify potential novel therapeutic targets. The top hit from this analysis was validated in vivo using PDX models of medulloblastoma implanted subcutaneously in the flank and orthotopically in the cerebellum of mice.Results: Informatics analysis identified the CDK4/6/CYCLIN D/RB pathway as a novel “druggable” pathway for multiple subgroups of medulloblastoma. Palbociclib, a highly specific inhibitor of CDK4/6, was found to inhibit RB phosphorylation and cause G1 arrest in PDX models of medulloblastoma. The drug caused rapid regression of Sonic hedgehog (SHH) and MYC-amplified group 3 medulloblastoma subcutaneous tumors and provided a highly significant survival advantage to mice bearing MYC-amplified intracranial tumors.Conclusions: Inhibition of CDK4/6 is potentially a highly effective strategy for the treatment of SHH and MYC-amplified group 3 medulloblastoma. Clin Cancer Res; 23(19); 5802–13. ©2017 AACR.